GLP-1 Insurance Coverage & Prior-Authorization Guide (2026): What's Covered and How to Get Approved
GLP-1 coverage in 2026: employer plans flat at 36%, PBM formularies, prior-auth rules, Medicare's live $50 Bridge, Medicaid by state, and how to appeal.
Whether a GLP-1 is covered still depends on who is paying and why. The same Wegovy or Zepbound prescription can cost a $25 copay, a $349 cash payment, or $50 through Medicare. It comes down to the plan, the diagnosis on the chart, and whether a prior authorization clears. Three things have changed since this guide first ran on June 2, 2026. The Medicare GLP-1 Bridge went live July 1 with a $50 copay. CVS Caremark set October 1, 2026 as the date Zepbound returns to its commercial formularies. And two employer surveys showed coverage has stopped growing.
The employer numbers are flat. The Business Group on Health polled 105 large self-funded employers in early 2026. It found 67% cover GLP-1s for weight management, but only 72% of those expect to keep doing so in 2027, and 10% say they likely will not. A broader survey of almost 300 employer health plans by the International Foundation of Employee Benefit Plans, reported by CNBC on July 8, found 36% cover GLP-1s for both diabetes and weight loss, unchanged from 2025. Another 60% cover them for diabetes only. Instead of adding coverage, 27% of employers steer workers to cash-pay platforms such as LillyDirect and NovoCare. Demand keeps climbing anyway. Gallup's July 7 poll put 11% of US adults on a GLP-1 for weight loss, up from 3% in 2024. For the 2027 risk, see what happens if your job drops GLP-1 coverage. For why the 36% has not budged, see employer GLP-1 coverage stuck at 36%.
A few terms this guide uses. A pharmacy benefit manager (PBM) is the company that runs a health plan's drug benefit; CVS Caremark, Express Scripts, and OptumRx are the big three. A formulary is the PBM's list of covered drugs. Prior authorization is a coverage request the plan must approve before a pharmacy can fill. Step therapy means trying a cheaper drug first. WAC, or wholesale acquisition cost, is the list price before any discount.
This guide maps the four paths people use: employer and commercial plans through their PBMs, Medicare, Medicaid, and cash or manufacturer programs. It also covers the prior authorization rules that decide approvals and how to appeal a denial. Every figure is dated and sourced, because formularies and prices in this category change every quarter. For the Medicare program in detail, see the Medicare GLP-1 Bridge Pricing Guide. For list and cash prices across products, see GLP-1 Drug Pricing: September 2026.
Commercial and employer plans: the PBM formulary
Most working-age people get GLP-1s through an employer plan run by one of three large PBMs: CVS Caremark, Express Scripts, or OptumRx. Two things decide access: whether the employer bought obesity coverage at all, and whether the PBM keeps the specific drug on its formulary. CVS Caremark dropped Zepbound on July 1, 2025 in favor of Wegovy. On May 28, 2026 it reversed course, adding Foundayo on June 1 and bringing Zepbound back October 1, 2026.
| Channel | Price | Source |
|---|---|---|
| CVS Caremark: Zepbound | Returns October 1, 2026 | CVS Health |
| CVS Caremark: Foundayo | Covered since June 1, 2026 | CNBC |
| CVS Caremark: Wegovy | Preferred | CVS Health |
| Express Scripts / Cigna | Both covered (with PA) | Evernorth |
Employer coverage in 2026: what the surveys show
Three surveys published between May and July 2026 describe the same picture. Most large employers cover GLP-1s for weight loss, mid-size and small ones mostly do not, and the overall share is no longer rising. The Business Group on Health polled 105 large self-funded employers. The International Foundation of Employee Benefit Plans (IFEBP) polled almost 300 employer health plans in June. Gallup surveyed 5,065 adults between May 28 and June 5.
| Channel | Price | Source |
|---|---|---|
| Large self-funded employers covering weight-management GLP-1s | 67% | MedCity News |
| Covering employers likely to drop coverage in 2027 | 10% | Healthcare Dive |
| Employers covering GLP-1s for diabetes and weight loss | 36% | CNBC |
| Employers covering for diabetes only | 60% | CNBC |
| Employers steering workers to cash-pay platforms | 27% | CNBC |
| US adults currently taking a GLP-1 for weight loss | 11% | Gallup |
| Firms with 5,000+ workers covering obesity GLP-1s | 43% | KFF 2025 Employer Survey |
Prior authorization criteria: what plans require
When a commercial plan covers obesity GLP-1s, it almost always gates them behind prior authorization. The criteria are similar across payers: a BMI threshold, documented related conditions, often a step-therapy trial of a cheaper drug, and a documented diet-and-exercise effort. Continued coverage usually depends on showing the drug is working.
| Channel | Price | Source |
|---|---|---|
| Initial PA: BMI threshold | 30+, or 27+ with a condition | SingleCare |
| Step therapy | Often required | SingleCare |
| Reauthorization | 5% or more weight loss | SingleCare |
| Initial authorization length (UnitedHealthcare) | 5 to 6 months | UnitedHealthcare |
Medicare: coverage by indication, plus the live $50 Bridge
Medicare Part D cannot cover a drug used only for weight loss, an exclusion written into the 2003 law that created the benefit. Part D does cover GLP-1s prescribed for an approved non-weight-loss use, and FDA approvals for heart risk, sleep apnea, and the liver disease MASH have widened that door. Since July 1, 2026, the Medicare GLP-1 Bridge adds weight-loss access at a flat $50 copay, processed by Humana outside the normal Part D flow. A separate Inflation Reduction Act (IRA) negotiated price for semaglutide starts January 1, 2027.
| Channel | Price | Source |
|---|---|---|
| Part D: weight loss only | Not covered | HHS ASPE |
| Part D: type 2 diabetes (Ozempic, Mounjaro) | Covered | KFF |
| Part D: Wegovy for heart risk | Covered (by indication) | FDA |
| Part D: Zepbound for sleep apnea | Covered (by indication) | FDA |
| Part D: Wegovy for MASH | Covered (by indication) | FDA |
| Medicare GLP-1 Bridge (weight loss) | $50/mo copay | CMS |
| IRA-negotiated semaglutide price | $274 per 30 days | BioPharma Dive |
Medicaid: coverage varies sharply by state
Medicaid coverage of GLP-1s for obesity is a patchwork that shrank in 2026. Diabetes coverage is near-universal across states, but weight-loss coverage is optional and several states dropped it. California's Medi-Cal ended weight-loss coverage at the start of the year, citing cost. States can also opt into the federal BALANCE Model for GLP-1 coverage through January 1, 2027.
| Channel | Price | Source |
|---|---|---|
| States covering obesity GLP-1s (fee-for-service) | 13 states | KFF |
| California Medi-Cal (weight loss) | Ended Jan 1, 2026 | Medi-Cal Rx (DHCS) |
| Medicaid: diabetes indication | Covered | KFF Health News |
| Patient cost in covering states | $0 to $4 | KFF |
Cash pay and manufacturer savings programs
For the uninsured, the excluded, and the denied, both manufacturers sell direct at cash prices well below list. Savings cards cut copays for the commercially insured but exclude anyone on Medicare, Medicaid, or other government coverage, and the diabetes-drug cards require a diabetes prescription. Prices below are from the manufacturer pages as of September 2, 2026.
| Channel | Price | Source |
|---|---|---|
| Wegovy injection self-pay (NovoCare Pharmacy) | $349/mo | NovoCare Pharmacy |
| Wegovy pill self-pay | $149 to $299/mo | NovoCare Pharmacy |
| Wegovy savings card (commercial coverage) | $0 to $25/mo | NovoCare |
| Zepbound self-pay vials (LillyDirect) | $299 to $449/mo | LillyDirect |
| Zepbound savings card (commercial coverage) | $25/mo | Zepbound.com |
| Ozempic / Mounjaro savings cards (diabetes) | $25/mo | Ozempic.com |
List prices and the 2026 to 2027 price-cut wave
List (WAC) prices are what an uninsured patient faces with no discount program, and what every coverage negotiation starts from. They are coming down. Novo Nordisk cut its list prices effective January 1, 2027, and the November 2025 MFN deal set a $245 Medicare price. TrumpRx, the federal cash-pay portal, routes patients to manufacturer self-pay prices and does not take insurance.
| Channel | Price | Source |
|---|---|---|
| Wegovy injection list (WAC) | $1,349/mo | White House |
| Zepbound list (WAC) | $1,088/mo | White House |
| Ozempic list (WAC) | $1,028/mo | White House |
| Novo Nordisk list-price cut | $675/mo | Novo Nordisk PR |
| Medicare MFN price | $245/mo | White House |
| TrumpRx portal | Launched Feb 5, 2026 | CNBC |
When you are denied: the appeals playbook
A prior authorization denial is not the end of the road. Federal rules give commercially insured patients set deadlines for an internal appeal and then an independent external review, and reviewers overturn close to half the cases they see. Match your response to the stated denial reason and supply exactly the documents the plan asked for. Medicare Bridge rejections are a special case: many turn out to be pharmacy routing errors.
| Channel | Price | Source |
|---|---|---|
| Internal appeal window | 180 days | HealthCare.gov |
| Insurer decision deadline | 30 or 60 days | KFF |
| External (independent) review | 4 months to file | HealthCare.gov |
| External-review overturn rate | ~47% | KFF |
| Medicare Bridge rejection at the pharmacy | Check the routing first | CMS |